NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.89 -0.68 (-0.88%) GOLD FUTURES
2,332.90 -60.00 (-2.51%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
52,683.62 -2,200.04 (-4.01%)
AZN Jan 2026 72.500 put
- Benzinga
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
On Thursday, Tango Therapeutics Inc. (NASDAQ:TNGX) announced that it will discontinue the development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, President and CEO. “We
- Business Wire
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
WILMINGTON, Del., May 23, 2024--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
- Zacks
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
